scispace - formally typeset
C

Christopher Timmermann

Researcher at Imperial College London

Publications -  46
Citations -  1165

Christopher Timmermann is an academic researcher from Imperial College London. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 9, co-authored 24 publications receiving 311 citations. Previous affiliations of Christopher Timmermann include University of Bologna.

Papers
More filters
Journal ArticleDOI

Predicting Responses to Psychedelics: A Prospective Study.

TL;DR: It seemed that baseline trait variables had the strongest effect on the change in well-being after a psychedelic experience, and the importance of extra-pharmacological factors in determining responses to a psychedelic was confirmed.
Journal ArticleDOI

Neural correlates of the DMT experience assessed with multivariate EEG

TL;DR: Investigation of the effects of IV DMT on the power spectrum and signal diversity of human brain activity recorded via multivariate EEG found the emergence of oscillatory activity within the delta and theta frequency bands was found to correlate with the peak of the experience - particularly its eyes-closed visual component.
Journal ArticleDOI

Increased global integration in the brain after psilocybin therapy for depression

TL;DR: In this paper , the authors assessed the subacute impact of psilocybin on brain function in two clinical trials of depression using functional magnetic resonance imaging (fMRI) at baseline and 1 d after the 25-mg dose.
Journal ArticleDOI

DMT Models the Near-Death Experience

TL;DR: A significant overlap in nearly all of the NDE phenomenological features is found when comparing DMT-induced NDEs with a matched group of ‘actual’ NDE experiencers, and a striking similarity between these states that warrants further investigation is revealed.
Journal ArticleDOI

Increased global integration in the brain after psilocybin therapy for depression

TL;DR: In this paper , the authors assessed the subacute impact of psilocybin on brain function in two clinical trials of depression using functional magnetic resonance imaging (fMRI) at baseline and 1 d after the 25-mg dose.